Tuesday, November 17, 2020
The Tomosynthesis Mammography Imaging Screening Trial (TMIST) was designed to see if 3-D mammography, or tomosynthesis, could help personalize screening and if 3-D is actually better than the less expensive 2-D mammography.
TMIST is the largest breast cancer screening trial in the United States, with a cost of $100 million and a planned enrollment of 165,000 women.
There's just one problem. The study is falling short on enrollment of patients and participating sites. Will this mean the death of TMIST?
For more details, see coverage of TMIST on Medscape:
NCI May 'Kill' Major Mammography Trial, Says Advisor
https://www.medscape.com/viewarticle/937918
Email Blood & Cancer at podcasts@mdedge.com.
How to Listen